These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

667 related articles for article (PubMed ID: 21659424)

  • 1. Genome-scale analysis of aberrant DNA methylation in colorectal cancer.
    Hinoue T; Weisenberger DJ; Lange CP; Shen H; Byun HM; Van Den Berg D; Malik S; Pan F; Noushmehr H; van Dijk CM; Tollenaar RA; Laird PW
    Genome Res; 2012 Feb; 22(2):271-82. PubMed ID: 21659424
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comprehensive profiling of DNA methylation in colorectal cancer reveals subgroups with distinct clinicopathological and molecular features.
    Ang PW; Loh M; Liem N; Lim PL; Grieu F; Vaithilingam A; Platell C; Yong WP; Iacopetta B; Soong R
    BMC Cancer; 2010 May; 10():227. PubMed ID: 20492682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epigenetic-genetic interactions in the APC/WNT, RAS/RAF, and P53 pathways in colorectal carcinoma.
    Suehiro Y; Wong CW; Chirieac LR; Kondo Y; Shen L; Webb CR; Chan YW; Chan AS; Chan TL; Wu TT; Rashid A; Hamanaka Y; Hinoda Y; Shannon RL; Wang X; Morris J; Issa JP; Yuen ST; Leung SY; Hamilton SR
    Clin Cancer Res; 2008 May; 14(9):2560-9. PubMed ID: 18451217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of the association between CIMP and BRAF in colorectal cancer by DNA methylation profiling.
    Hinoue T; Weisenberger DJ; Pan F; Campan M; Kim M; Young J; Whitehall VL; Leggett BA; Laird PW
    PLoS One; 2009 Dec; 4(12):e8357. PubMed ID: 20027224
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutations in both KRAS and BRAF may contribute to the methylator phenotype in colon cancer.
    Nagasaka T; Koi M; Kloor M; Gebert J; Vilkin A; Nishida N; Shin SK; Sasamoto H; Tanaka N; Matsubara N; Boland CR; Goel A
    Gastroenterology; 2008 Jun; 134(7):1950-60, 1960.e1. PubMed ID: 18435933
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency.
    Dawson H; Galván JA; Helbling M; Muller DE; Karamitopoulou E; Koelzer VH; Economou M; Hammer C; Lugli A; Zlobec I
    Int J Cancer; 2014 May; 134(10):2342-51. PubMed ID: 24166180
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular dissection of premalignant colorectal lesions reveals early onset of the CpG island methylator phenotype.
    Yamamoto E; Suzuki H; Yamano HO; Maruyama R; Nojima M; Kamimae S; Sawada T; Ashida M; Yoshikawa K; Kimura T; Takagi R; Harada T; Suzuki R; Sato A; Kai M; Sasaki Y; Tokino T; Sugai T; Imai K; Shinomura Y; Toyota M
    Am J Pathol; 2012 Nov; 181(5):1847-61. PubMed ID: 22995252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.
    Lee S; Cho NY; Choi M; Yoo EJ; Kim JH; Kang GH
    Pathol Int; 2008 Feb; 58(2):104-13. PubMed ID: 18199160
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Down-regulation of p21 (CDKN1A/CIP1) is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer.
    Ogino S; Kawasaki T; Kirkner GJ; Ogawa A; Dorfman I; Loda M; Fuchs CS
    J Pathol; 2006 Oct; 210(2):147-54. PubMed ID: 16850502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations.
    Ogino S; Kawasaki T; Kirkner GJ; Loda M; Fuchs CS
    J Mol Diagn; 2006 Nov; 8(5):582-8. PubMed ID: 17065427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrative Genome-Scale DNA Methylation Analysis of a Large and Unselected Cohort Reveals 5 Distinct Subtypes of Colorectal Adenocarcinomas.
    Fennell L; Dumenil T; Wockner L; Hartel G; Nones K; Bond C; Borowsky J; Liu C; McKeone D; Bowdler L; Montgomery G; Klein K; Hoffmann I; Patch AM; Kazakoff S; Pearson J; Waddell N; Wirapati P; Lochhead P; Imamura Y; Ogino S; Shao R; Tejpar S; Leggett B; Whitehall V
    Cell Mol Gastroenterol Hepatol; 2019; 8(2):269-290. PubMed ID: 30954552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Promoter methylation of specific genes is associated with the phenotype and progression of colorectal adenocarcinomas.
    Kim JC; Choi JS; Roh SA; Cho DH; Kim TW; Kim YS
    Ann Surg Oncol; 2010 Jul; 17(7):1767-76. PubMed ID: 20077021
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MGMT and MLH1 promoter methylation versus APC, KRAS and BRAF gene mutations in colorectal cancer: indications for distinct pathways and sequence of events.
    de Vogel S; Weijenberg MP; Herman JG; Wouters KA; de Goeij AF; van den Brandt PA; de Bruïne AP; van Engeland M
    Ann Oncol; 2009 Jul; 20(7):1216-22. PubMed ID: 19164452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multiple sporadic colorectal cancers display a unique methylation phenotype.
    Gonzalo V; Lozano JJ; Alonso-Espinaco V; Moreira L; Muñoz J; Pellisé M; Castellví-Bel S; Bessa X; Andreu M; Xicola RM; Llor X; Ruiz-Ponte C; Carracedo A; Jover R; Castells A; Balaguer F;
    PLoS One; 2014; 9(3):e91033. PubMed ID: 24643221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unique patterns of CpG island methylation in inflammatory bowel disease-associated colorectal cancers.
    Olaru AV; Cheng Y; Agarwal R; Yang J; David S; Abraham JM; Yu W; Kwon JH; Lazarev M; Brant SR; Marohn MR; Hutcheon DF; Harpaz N; Meltzer SJ; Mori Y
    Inflamm Bowel Dis; 2012 Apr; 18(4):641-8. PubMed ID: 21830278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High frequency of genes' promoter methylation, but lack of BRAF V600E mutation among Iranian colorectal cancer patients.
    Naghibalhossaini F; Hosseini HM; Mokarram P; Zamani M
    Pathol Oncol Res; 2011 Dec; 17(4):819-25. PubMed ID: 21455633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rectal cancer profiling identifies distinct subtypes in India based on age at onset, genetic, epigenetic and clinicopathological characteristics.
    Laskar RS; Ghosh SK; Talukdar FR
    Mol Carcinog; 2015 Dec; 54(12):1786-95. PubMed ID: 25418895
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The CpG island methylator phenotype correlates with long-range epigenetic silencing in colorectal cancer.
    Karpinski P; Ramsey D; Grzebieniak Z; Sasiadek MM; Blin N
    Mol Cancer Res; 2008 Apr; 6(4):585-91. PubMed ID: 18403637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel application of structural equation modeling to correlation structure analysis of CpG island methylation in colorectal cancer.
    Tanaka N; Huttenhower C; Nosho K; Baba Y; Shima K; Quackenbush J; Haigis KM; Giovannucci E; Fuchs CS; Ogino S
    Am J Pathol; 2010 Dec; 177(6):2731-40. PubMed ID: 21037082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MGMT promoter methylation, loss of expression and prognosis in 855 colorectal cancers.
    Shima K; Morikawa T; Baba Y; Nosho K; Suzuki M; Yamauchi M; Hayashi M; Giovannucci E; Fuchs CS; Ogino S
    Cancer Causes Control; 2011 Feb; 22(2):301-9. PubMed ID: 21140203
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.